News about Global Pharma

Immix Biopharma Prices USD 100 Million Stock and Pre-Funded Warrant Offering

Immix Biopharma has priced its USD 100 million offering of common stock and pre-funded warrants, with plans to use the proceeds—alongside existing cash reserves—to advance the development of NXC-201 and support working capital and general corporate needs.

Global Pharma | 08/12/2025 | By Dineshwori |  131

OTR Therapeutics Raises USD 100 Million to Advance Transformative Therapies

OTR Therapeutics has secured USD 100 million in Series A funding to accelerate the development of its pipeline of differentiated therapies aimed at addressing major unmet needs across immunology, inflammation, oncology, and other disease areas.

Global Pharma | 05/12/2025 | By Dineshwori |  351

Formycon, MS Pharma Ink MENA Deal for Keytruda Biosimilar FYB206

Formycon has signed an exclusive commercialisation agreement with MS Pharma for its Keytruda biosimilar candidate FYB206 in the MENA region. The deal includes an upfront payment, milestone-based fees, and a significant share of regional gross profits generated in the region.

Global Pharma | 05/12/2025 | By Dineshwori |  123

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Global Pharma | 05/12/2025 | By Dineshwori |  128

Nona Biosciences Taps Dr. Hongjiang Miao to Advance A3 Strategy and AI-Driven Drug Discovery

Dr. Hongjiang Miao will lead the Nona AI team to advance the company's A3 (Antibody engineering × AI × Automation) strategy and further transform Nona into an AI-driven drug discovery company.

Global Pharma | 04/12/2025 | By Dineshwori |  138

WuXi Biologics Extends CRDMO Footprint to Qatar

WuXi Biologics has signed an MoU with the Qatar Free Zones Authority (QFZ) to expand its global footprint into the Middle East. The partnership sets the stage for the company’s first integrated CRDMO centre in the region, strengthening its worldwide research, development, and manufacturing capabilities.

Global Pharma | 02/12/2025 | By Dineshwori |  329

Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody

Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.

Global Pharma | 02/12/2025 | By Dineshwori |  263

TempraMed Technologies Inks Distribution Agreement with Guri

The partnership marks TempraMed’s entry into a broader global rollout, with the Guri agreement serving as the first step in a series of regional distribution deals planned across Europe, the Middle East, North America, and Asia.

Global Pharma | 28/11/2025 | By Dineshwori |  179

India and Switzerland Explore Pharma-Biotech Collaboration After High-Level Meeting

The talks emphasised avenues for Swiss companies to invest in India’s pharma and biotech industries and to leverage the country’s robust healthcare market.

Global Pharma | 28/11/2025 | By Darshana |  144

Valneva to Further Consolidate its Operations in France

The move is part of Valneva’s strategy to optimise its global footprint, enhance operational efficiency in France, and unify all research and development efforts at its Vienna hub.

Global Pharma | 28/11/2025 | By Dineshwori |  216